Edition:
United States

Bavarian Nordic A/S (BAVA.F)

BAVA.F on Frankfurt Stock Exchange

35.77EUR
17 Oct 2017
Change (% chg)

-- (--)
Prev Close
€35.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
237
52-wk High
€59.96
52-wk Low
€25.00

Latest Key Developments (Source: Significant Developments)

Bavarian Nordic wins big smallpox vaccine order for U.S. government
Thursday, 28 Sep 2017 01:12am EDT 

Sept 28 (Reuters) - BAVARIAN NORDIC A/S :SECURES CONTRACT AWARD FOR SUPPLY OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE TO THE U.S. GOVERNMENT.INITIAL BASE AWARD SECURES ADDITIONAL IMVAMUNE BULK CONTRACT OF USD 100 MILLION.CONTRACT INCLUDES INITIAL OPTIONS VALUED AT USD 439 MILLION.POTENTIAL VALUE OF INITIAL BASE AND OPTIONAL AWARDS IS IN EXCESS OF $539 MILLION.BAVARIAN NORDIC-AWARD OF CONTRACT FROM BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY FOR PROCUREMENT OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE.  Full Article

Bavarian Nordic provides update on its RSV vaccine
Thursday, 21 Sep 2017 04:13am EDT 

Sept 21 (Reuters) - BAVARIAN NORDIC A/S ::REG-BAVARIAN NORDIC PROVIDES UPDATE ON ITS UNIVERSAL RSV VACCINE.SAYS ‍RANDOMIZED, PLACEBO-CONTROLLED TRIAL, EVALUATED SAFETY, TOLERABILITY AND IMMUNOGENICITY OF RECOMBINANT VACCINE IN 421 HEALTHY ADULTS AGED 55 AND OLDER​.‍WILL PARTNER WITH A GLOBAL CRO TO DEVELOP A NOVEL AND DIFFERENTIATED APPROACH TO RSV CHALLENGE MODEL​.‍AT 6 MONTH FOLLOW UP, A PERSISTENT ANTIBODY RESPONSE AGAINST MULTIPLE RSV TARGETS CAN STILL BE OBSERVED​.  Full Article

Bavarian Nordic says independent Data Monitoring Committee determined continuation of Phase 3 prospect study of Prostvac is futile
Thursday, 14 Sep 2017 04:02pm EDT 

Sept 14 (Reuters) - Bavarian Nordic A/S - :Independent Data Monitoring Committee recommends discontinuation of Bavarian Nordic's Phase 3 study of Prostvac in metastatic prostate cancer.An independent Data Monitoring Committee determined continuation of Phase 3 prospect study of Prostvac is futile.Contents of this announcement do not affect the company's expectations for the financial results for 2017.  Full Article

Bavarian Q2 EBIT at DKK 102.3 million
Friday, 25 Aug 2017 01:54am EDT 

Aug 25 (Reuters) - BAVARIAN NORDIC A/S ::‍MAINTAINS ITS FINANCIAL EXPECTATIONS FOR 2017​.Q2 REVENUE DKK 397.3‍​ MILLION VERSUS DKK 116.6 MILLION YEAR AGO.Q2 EBIT DKK 102.3 ‍​ MILLION VERSUS LOSS DKK 54.0 MILLION YEAR AGO.  Full Article

Bavarian Nordic announces price for shares to be issued to Johnson & Johnson Innovation
Wednesday, 9 Aug 2017 02:24pm EDT 

Aug 9 (Reuters) - Bavarian Nordic A/S ::Bavarian Nordic A/S says subscription price is dkk 405.1578 per share of dkk 10.Bavarian Nordic A/S says jjdc will subscribe for Bavarian Nordic shares for $33 million, corresponding to dkk 207 million.  Full Article

Bavarian Nordic: positive data from Phase 2 study of a universal RSV vaccine
Tuesday, 27 Jun 2017 07:59am EDT 

June 27 (Reuters) - BAVARIAN NORDIC A/S :REG-BAVARIAN NORDIC ANNOUNCES POSITIVE DATA FROM ONGOING PHASE 2 STUDY INVESTIGATING A UNIVERSAL RSV VACCINE.SAYS ‍RESULTS CONFIRM INDUCTION OF ANTIBODIES (IGA) ASSOCIATED WITH MUCOSAL RESPONSES​.‍SAYS VACCINE WAS SHOWN TO BE BOTH WELL TOLERATED AND IMMUNOGENIC AT BOTH DOSE LEVELS INVESTIGATED.​.  Full Article

Bavarian Nordic launches share buy-back program to hedge incentive scheme obligations
Thursday, 18 May 2017 02:30am EDT 

May 18 (Reuters) - Bavarian Nordic A/S :REG-BAVARIAN NORDIC LAUNCHES SHARE BUY-BACK PROGRAM TO HEDGE INCENTIVE SCHEME OBLIGATIONS.COMPANY INTENDS TO BUY BACK 12,156 OF ITS OWN SHARES..  Full Article

Bavarian Nordic appoints Dr. Tommi Kainu as Chief Business Officer, effective july 1
Wednesday, 10 May 2017 02:59am EDT 

May 10 (Reuters) - BAVARIAN NORDIC A/S :APPOINTS DR. TOMMI KAINU AS CHIEF BUSINESS OFFICER, EFFECTIVE JULY 1.  Full Article

Bavarian nordic Q1 EBIT loss narrows to DKK 3.1 million
Thursday, 4 May 2017 01:38am EDT 

May 4 (Reuters) - Bavarian Nordic A/S ::Q1 EBIT LOSS 3.1 DKK MILLION VERSUS LOSS DKK 152.7 MILLION YEAR AGO.Q1 REVENUE DKK 198 MILLION VERSUS DKK 23 MILLION YEAR AGO.MAINTAINS ITS FINANCIAL EXPECTATIONS FOR 2017.  Full Article

Valneva signs new EB66 commercial license with Bavarian Nordic
Tuesday, 18 Apr 2017 01:01am EDT 

April 18 (Reuters) - Valneva SE ::Announces signing of a new EB66 commercial license with Bavarian Nordic <<>>.Valneva's EB66 cell-line licensed to Bavarian Nordic for MVA-BN based product candidates.Valneva to support process development.The agreement grants Bavarian Nordic the rights to develop and commercialize multiple poxvirus-based vaccines on the EB66 cell-line.  Full Article

SGS and Bavarian Nordic developing challenge strain to combat respiratory virus​

ZURICH SGS and Bavarian Nordic are teaming up to develop a virus challenge strain to combat a common respiratory illness.